Evidence map›Paper›PMID 41876641›Full record

ArticleCommunications biology2026

Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome.

Toshihiko Nambara, Joo Yeon Lee, Masaki Minami, Soichiro Okamoto, Keiji Kawatani, Haruna Kusakabe, Hidetaka Yoshimatsu, Katsuya Hirata, Kazuto Yoshimi, Tomoji Mashimo and 4 more

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Toshihiko Nambara *Department of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Joo Yeon Lee *Department of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Masaki MinamiDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Soichiro OkamotoDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Keiji KawataniDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Haruna KusakabeDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.
Hidetaka YoshimatsuDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0003-2985-1338
Katsuya HirataDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0003-3148-9892
Kazuto YoshimiDivision of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.ORCID http://orcid.org/0000-0001-5110-1440
Tomoji MashimoDivision of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, 108-8639, Japan.ORCID http://orcid.org/0000-0001-7543-7301
Akira TanaveLaboratory for Mouse Genetic Engineering, RIKEN Center for Biosystems Dynamics Research, Suita, Osaka, 565-0871, Japan.
Kenta SumiyamaLaboratory of Animal Genetics and Breeding, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Aichi, 464-8601, Japan.ORCID http://orcid.org/0000-0001-8785-5439
Keiichi OzonoDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0000-0002-6517-8825
Yasuji KitabatakeDepartment of Pediatrics, Graduate School of Medicine, The University of Osaka, Suita, Osaka, 565-0871, Japan. ykitaba@ped.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-2907-9512

Funding

Japan Agency for Medical Research and Development (AMED) JP19bm0804009Japan Agency for Medical Research and Development (AMED) JP22bm1123004MEXT | Japan Society for the Promotion of Science (JSPS) JP18K15709MEXT | Japan Society for the Promotion of Science (JSPS) JP19H03619MEXT | Japan Society for the Promotion of Science (JSPS) JP21K19448MEXT | Japan Society for the Promotion of Science (JSPS) JP22H03039
6 · The paper itself

Abstract

A reduction in the number of neurons and an increased susceptibility to apoptosis are one of the characteristic features observed in Down syndrome (DS). However, the multifaceted actions of chromosomal aneuploidy hinder the elucidation of the underlying mechanism. Here, using neurons and astrocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs), we aimed to clarify the neuropathology of DS by focusing on aneuploidy-associated stress and the dosage effects of specific genes. Human chromosomal trisomies 13, 18, and 21 exert a stress response on neurons, resulting in the accumulation of protein aggregates. In addition, DYRK1A overdosage in trisomy 21 astrocytes causes intrinsic activation of the NLRP3 inflammasome, which leads to the release of inflammatory cytokines. These dual actions reciprocally interact and enhance neuronal apoptosis in trisomy 21. Notably, correction of DYRK1A copy number successfully rescued apoptotic neural death in combination with a chemical chaperone treatment. Our study provides insights into the neuropathological mechanism of DS and its potential therapeutic strategy.

Indexed as

AneuploidyDown SyndromeGene DosageNeuronsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesApoptosisAstrocytesDyrk KinasesHumansInduced Pluripotent Stem CellsDyrk KinasesProtein Serine-Threonine KinasesProtein-Tyrosine Kinases

Identifiers

PMID41876641
PMCPMC13179340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.